CDX2 and gastric adenocarcinoma: According to Park et al (28), CDX2 expression was found in ~60.9% of gastric adenocarcinoma patients, highlighting the diagnostic value of organ-specific immunohistochemical markers in differentiating between adenocarcinoma origins.